Replies to post #198393 on Option Millionaires

[uranium-pinto-beans]

$GILD Gilead Q1 results 'outstanding,' says Wells Fargo
After Gilead reported stronger than expected Q1 results, Wells Fargo thinks that the company's Sovaldi sales likely exceeded most Street estimates. The firm thinks the strong Sovaldi launch bodes well for the drug's long-term outlook. It keeps an $87-$91 price target and Outperform rating on the stock